Star Combo Pharma Ltd. (AU:S66)
ASX:S66
S66 Stock Chart & Stats
AU$0.25
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.25
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.10 - AU$0.28
Previous CloseN/A
Volume100.00K
Average Volume (3M)6.77K
Market Cap
AU$27.00M
Enterprise ValueAU$31.21M
Total Cash (Recent Filing)AU$18.18M
Total Debt (Recent Filing)AU$8.29M
Price to Earnings (P/E)21.2
Beta-0.40
Next Earnings
Sep 01, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield1.54%
Share Statistics
EPS (TTM)<0.01
Shares Outstanding135,002,980
10 Day Avg. Volume4,300
30 Day Avg. Volume6,768
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)0.63
Price to Sales (P/S)0.86
P/FCF Ratio2.08
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Margin RecoveryA large improvement in net margin to ~18.9% materially increases underlying earnings power and operating leverage. Sustained higher margins support consistent cash generation and returns, enabling reinvestment or distributions if management maintains pricing discipline and cost controls.
Strong Free Cash Flow ConversionRobust 2025 cash generation with FCF near net income indicates high earnings quality and internal funding capacity. Reliable cash conversion supports capex, working capital, or shareholder returns and reduces reliance on external financing for strategic investments over the medium term.
Low Leverage / Balance-sheet FlexibilityVery low leverage provides financial flexibility and reduces refinancing and interest-rate risk. A conservative balance sheet allows the company to fund growth or withstand downturns from internal cash or modest borrowing without straining liquidity or credit capacity.
Bears Say
Declining RevenueTop-line contraction limits the company's long-term growth runway and reduces the scale available to absorb fixed costs. Continued revenue decline would make maintaining improved margins harder and constrain expansion, distribution gains, and reinvestment prospects.
Earnings And Cash-flow VolatilityA history of multi-year losses and cash-flow swings increases execution risk and hampers reliable planning. Volatility complicates capital-allocation decisions and investor confidence, meaning the recent strong year must be repeated to demonstrate durable operational control.
Recovery Is Margin-driven, Not Volume-drivenProfit recovery relying on margin gains rather than revenue growth is less durable: cost or pricing gains can reverse and quickly erode profits. Long-term stability requires restored demand or market-share growth to complement margin improvements.
Star Combo Pharma Ltd. News
S66 FAQ
What was Star Combo Pharma Ltd.’s price range in the past 12 months?
Star Combo Pharma Ltd. lowest share price was AU$0.10 and its highest was AU$0.28 in the past 12 months.
What is Star Combo Pharma Ltd.’s market cap?
Star Combo Pharma Ltd.’s market cap is AU$27.00M.
When is Star Combo Pharma Ltd.’s upcoming earnings report date?
Star Combo Pharma Ltd.’s upcoming earnings report date is Sep 01, 2026 which is in 150 days.
How were Star Combo Pharma Ltd.’s earnings last quarter?
Star Combo Pharma Ltd. released its earnings results on Feb 25, 2026. The company reported AU$0.003 earnings per share for the quarter, beating the consensus estimate of N/A by AU$0.003.
Is Star Combo Pharma Ltd. overvalued?
According to Wall Street analysts Star Combo Pharma Ltd.’s price is currently Overvalued.
Does Star Combo Pharma Ltd. pay dividends?
Star Combo Pharma Ltd. pays a Notavailable dividend of AU$0.004 which represents an annual dividend yield of 1.54%. See more information on Star Combo Pharma Ltd. dividends here
What is Star Combo Pharma Ltd.’s EPS estimate?
Star Combo Pharma Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Star Combo Pharma Ltd. have?
Star Combo Pharma Ltd. has 135,002,980 shares outstanding.
What happened to Star Combo Pharma Ltd.’s price movement after its last earnings report?
Star Combo Pharma Ltd. reported an EPS of AU$0.003 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -4.878%.
Which hedge fund is a major shareholder of Star Combo Pharma Ltd.?
Currently, no hedge funds are holding shares in AU:S66
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Star Combo Pharma Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
82.20%
12-Months-Change
Fundamentals
Return on Equity
14.06%
Trailing 12-Months
Asset Growth
8.47%
Trailing 12-Months
Company Description
Star Combo Pharma Ltd.
Star Combo Pharma Limited engages in the manufacturing and distribution of health food products and nutritional supplements in Australia and China. The company operates in two segments, Star Combo and Austoyou Retail. It develops, manufactures, markets, and sells natural health supplements and skin care products. The company provides its products through e-commerce platform to Chinese health product consumers; and two retail stores in Sydney. Star Combo Pharma Limited was founded in 2004 and is based in Smithfield, Australia.
Technical Analysis
Zoono Group Limited
―
Nanollose Ltd.
―
Skin Elements Limited
―
Lumos Diagnostics Holdings Ltd.
―
―